Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine
Wall Street sees new treatments as an untapped goldmine, full of consumers who are willing to pay out-of-pocket for better options, reminiscent of the boom in GLP-1 weight-loss drugs.
Wall Street sees new treatments as an untapped goldmine, full of consumers who are willing to pay out-of-pocket for better options, reminiscent of the boom in GLP-1 weight-loss drugs.
What's Your Reaction?
